Edwards Lifesciences (NYSE:EW) Price Target Raised to $90.00

Edwards Lifesciences (NYSE:EW) had its price objective upped by Truist Financial from $87.00 to $90.00 in a research note released on Monday morning,Benzinga reports. The firm currently has a hold rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company lifted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Robert W. Baird set a $83.00 price target on Edwards Lifesciences in a report on Friday, October 31st. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Stock Down 1.5%

Shares of NYSE:EW opened at $82.86 on Monday. The stock’s fifty day simple moving average is $77.72 and its 200-day simple moving average is $77.18. Edwards Lifesciences has a 52-week low of $64.89 and a 52-week high of $87.09. The company has a market capitalization of $48.65 billion, a P/E ratio of 11.92, a P/E/G ratio of 3.97 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business posted $0.67 EPS. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.29% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in EW. Norges Bank purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the period. Nuveen LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth approximately $330,881,000. Marshall Wace LLP boosted its position in shares of Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after purchasing an additional 3,864,908 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.